The project REEM 2013-2016 is to study the pathogenesis of MS to develop new biomarkers and therapeutic approaches. Our goal is to improve the quality of life of patients with MS.

In the new edition of 2012 RETICs REEM program: "Multiple Sclerosis, pathogenesis and new therapies," focuses on two areas of work or programs. The programs combine research on the pathogenesis of multiple sclerosis and encompass the opportunity to develop biomarkers and develop new therapies:

  • Program 1: Genomics Program
  • 2: Immunology of Multiple Sclerosis.

To achieve the results we have proposed a consortium of 15 research groups and hospitals throughout Spain. The results of this program enhance the understanding of the origin of the disease and the development of new treatments and new diagnostic tools provide ayudarána physicians make new decisions to control the disease.